[Cost analysis of the use of botulinum toxin type A in Spain.]
Conclusions: The appropriate BoNT-A choice would lead to considerablesavings for the National Health System. Botox® would generatelower costs per patient than other BoNT-A products in 9 out of 12 scenariosconsidered. PMID: 24951903 [PubMed - as supplied by publisher] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - June 22, 2014 Category: Drugs & Pharmacology Authors: De Andrés-Nogales F, Morell A, Aracil J, Torres C, Oyagüez I, Casado MA Tags: Farm Hosp Source Type: research

Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors.
CONCLUSIONS:The results of this national survey confirm that clinical experts on the use of BTX- -A therapy for spasticity after stroke agree on the need to initiate rehabilitation treatment immediately after BTX--A injection: muscle stretching exercises, eventually combined with neuromuscular electrical stimulation, may enhance the effect of BTX--A therapy. Outcome after BTX--A therapy should be assessed at repeated follow--up visits. PMID: 24963604 [PubMed - as supplied by publisher] (Source: European Journal of Physical and Rehabilitation Medicine)
Source: European Journal of Physical and Rehabilitation Medicine - June 19, 2014 Category: Rehabilitation Authors: Franceschini M, Iocco M, Molteni F, Santamato A, Smania N Tags: Eur J Phys Rehabil Med Source Type: research

Comparison of efficacy and diffusion of three formulations of botulinum toxin type A in two patients with forehead hyperhidrosis
(Source: Clinical And Experimental Dermatology)
Source: Clinical And Experimental Dermatology - June 16, 2014 Category: Dermatology Authors: E. J. Ko, S. K. Mun, I. Y. Oh, T. R. Kwon, B. J. Kim, M. N. Kim Tags: CPD ● Therapeutic vignette Source Type: research

Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial.
CONCLUSIONS: Adhesive taping of wrist and finger flexor muscles appeared to enhance the effect of botulinum toxin type A therapy more than daily manual muscle stretching combined with passive articular mobilization and palmar splint. PMID: 24917588 [PubMed - as supplied by publisher] (Source: Clinical Rehabilitation)
Source: Clinical Rehabilitation - June 10, 2014 Category: Rehabilitation Authors: Santamato A, Micello MF, Panza F, Fortunato F, Picelli A, Smania N, Logroscino G, Fiore P, Ranieri M Tags: Clin Rehabil Source Type: research

Platysma synkinesis in facial palsy and botulinum toxin type A
ConclusionPlatysma involvement represents a recurring and symptomatic problem in patients affected by synkinetic recovery following facial palsy. After BoNT‐A injections, there is a reduction in platysma synkinesis and related symptoms. Level of Evidence4. Laryngoscope, 2014 (Source: The Laryngoscope)
Source: The Laryngoscope - May 30, 2014 Category: ENT & OMF Authors: Anna Dall'Angelo, Silvia Mandrini, Vittorio Sala, Chiara Pavese, Ettore Carlisi, Mario Comelli, Elena Dalla Toffola Tags: Head and Neck Source Type: research

Valeant sweetens takeover bid for Allergan
Canadian drug maker Valeant Pharmaceuticals International Inc. has added more cash to its offer to buy Allergan Inc., Reuters reports. The updated offer values U.S.-based Allergan, which makes Botox, at $49.44 billion. That translates to about $58.30 per Allergan share in cash, which is $10 more per share than the previous offer. Read more here. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 28, 2014 Category: American Health Source Type: research

Therapeutic Synergism in the Treatment of Post-stroke Arm Paresis Utilizing Botulinum Toxin, Robotic Therapy, and Constraint-induced Movement Therapy
Botulinum toxin type A (BtxA) injection, constraint-induced movement therapy (CIMT), and robotic therapy (RT) each represent promising approaches to enhance arm motor recovery after stroke. To provide more effective treatment for a 50-year-old man with severe left spastic hemiparesis, we attempted to facilitate CIMT with adaptive approaches to extend the wrist and fingers using RT for 10 consecutive weeks after BtxA injection. This combined treatment resulted in substantial improvements in arm function and the amount of arm use in activities of daily living, and may be effective for stroke patients with severe arm paresis. (Source: PM and R)
Source: PM and R - May 28, 2014 Category: Rehabilitation Authors: Takashi Takebayashi, Satoru Amano, Keisuke Hanada, Atsushi Umeji, Kayoko Takahashi, Tetsuo Koyama, Kazuhisa Domen Source Type: research

Committee Opinion No. 604: OnabotulinumtoxinA and the Bladder.
Authors: Abstract : In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatment option for women. Symptoms of overactive bladder have been shown to significantly improve after onabotulinumtoxinA injections compared with no intervention, placebo, pharmacological treatments, and bladder instillation technique. Before considering medical or surgical treatment, all patients in whom overactive bladder is diagnosed should receive instruction in behavioral techniques (eg, bladder retraining...
Source: Obstetrics and Gynecology - May 25, 2014 Category: OBGYN Tags: Obstet Gynecol Source Type: research

Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design.
CONCLUSION: BoNT-A injected directly into painful muscle groups improves average pain scores and certain aspects of quality of life in patients experiencing severe cervical and shoulder girdle myofascial pain. PMID: 24842179 [PubMed - in process] (Source: Anesthesia and Analgesia)
Source: Anesthesia and Analgesia - May 24, 2014 Category: Anesthesiology Authors: Nicol AL, Wu II, Ferrante FM Tags: Anesth Analg Source Type: research

Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X3 inhibits the release of a pain mediator
The P2X purinoceptor 3 (P2X3) is predominantly expressed on nociceptive sensory neurons and plays a crucial role in signaling leading to chronic inflammatory pain and some features of neuropathic pain. Thus, it provides a potential target for pain therapeutics.Botulinum toxin type A (BoNT/A) effectively relieves certain types of pain through inhibiting the neuronal release of pain peptides. Recombinant single-chain variable fragment, scFv, was generated against the extracellular domain of P2X3, using phage display technology. The genes encoding the scFv and BoNT/A without N-terminal binding domain (LC-HN-HCN/A) were ligate...
Source: BJ Structure - May 20, 2014 Category: Biochemistry Authors: H Ma, J Meng, J Wang, S Hearty, J Dolly, R O'Kennedy Tags: BJ Biomolecules Source Type: research

Effects of botulinum toxin type A on non‐injected bi‐articular muscle include a narrower length range of force exertion and increased passive force
Conclusions: Effects of BTX‐A appear to not be limited to decreased active muscle tone, but may cause also a narrower active range of movement and increased passive resistance. Through spread of BTX‐A to a bi‐articular muscle, such effects are plausible for both joints spanned. Muscle Nerve 49: 866–878, 2014 (Source: Muscle and Nerve)
Source: Muscle and Nerve - May 17, 2014 Category: Internal Medicine Authors: Filiz Ateş, Can A. Yucesoy Tags: Research Article Source Type: research

Endoscopic suture repair of a large mucosal perforation during peroral endoscopic myotomy for treatment of achalasia
Mucosal perforations occur in about 10% to 15% of peroral endoscopic myotomy (POEM) procedures and are usually closed with clips. However, accidental perforations because of submucosal fibrosis from prior Botox (Allergan Inc., Irvine, CA) injections, balloon dilations (BDs), or other manipulations can be difficult to close (Fig. 1). A 40-year-old man with stage 2, type I achalasia and multiple prior BDs underwent POEM for dysphagia. Extensive submucosal fibrosis from prior BDs made extension of the tunnel at the gastroesophageal junction challenging. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - May 13, 2014 Category: Gastroenterology Authors: Rani Modayil, David Friedel, Stavros N. Stavropoulos Tags: VideoGIE Source Type: research

Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons
Summary: Immunohistochemical and behavioral data suggest that botulinum toxin type A antinociceptive activity, dependent on toxin’s axonal transport to the central nervous system, is mediated by capsaicin-sensitive neurons.Abstract: Unlike most classical analgesics, botulinum toxin type A (BoNT/A) does not alter acute nociceptive thresholds, and shows selectivity primarily for allodynic and hyperalgesic responses in certain pain conditions. We hypothesized that this phenomenon might be explained by characterizing the sensory neurons targeted by BoNT/A in the central nervous system after its axonal transport. BoNT/A&r...
Source: Pain - May 5, 2014 Category: Anesthesiology Authors: Ivica Matak, Ornella Rossetto, Zdravko Lacković Tags: Research papers Source Type: research

Intact muscle compartment exposed to botulinum toxin type A shows compromised intermuscular mechanical interaction
Conclusion EMFT is diminished. That BTX‐A compromises intermuscular mechanical interaction can be relevant clinically, since recent studies indicate that such interaction plays a role in the abnormal mechanics of spastic muscle. © 2014 Wiley Periodicals, Inc. (Source: Muscle and Nerve)
Source: Muscle and Nerve - May 3, 2014 Category: Internal Medicine Authors: Can A. Yucesoy, Ahu Nur Turkoğlu, Sevgi Umur, Filiz Ateş Tags: Research Article Source Type: research

Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy
(Source: PM and R)
Source: PM and R - May 2, 2014 Category: Rehabilitation Authors: Linda J. Michaud, Emily J. Louden, William C. Lippert, Allison J. Allgier, Susan L. Foad, Charles T. Mehlman Source Type: research

Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy
To evaluate functional outcomes and the impact on surgical interventions after the use of botulinum neurotoxin type A (BoNT-A) for muscle imbalance, cocontractions, or contractures with neonatal brachial plexus palsy. (Source: PM and R)
Source: PM and R - May 2, 2014 Category: Rehabilitation Authors: Linda J. Michaud, Emily J. Louden, William C. Lippert, Allison J. Allgier, Susan L. Foad, Charles T. Mehlman Source Type: research

Mo1917 Preclinical Trial of Botulinum Toxin Type a Injection in the Treatment of Gastric Cancer
(Source: Gastroenterology)
Source: Gastroenterology - May 1, 2014 Category: Gastroenterology Authors: Chun-Mei Zhao, Yoku Hayakawa, Christoph B. Westphalen, Sureshkumar Muthupalani, Helene Johannessen, Gøran Andersen, James G. Fox, Timothy C. Wang, Duan Chen Source Type: research

Mo2054 Preclinical Trial of Gastric Injection of Botulinum Toxin Type a As Weight-Loss-Surgery
(Source: Gastroenterology)
Source: Gastroenterology - May 1, 2014 Category: Gastroenterology Authors: Helene Johannessen, Magnus K. Olsen, Nikki Cassie, Perry Barrett, Jens F. Rehfeld, Jens J. Holst, Baard Kulseng, Chun-Mei Zhao, Duan Chen Source Type: research

Early postoperative treatment of thyroidectomy scars using botulinum toxin: A split‐scar, double‐blind randomized controlled trial
Abstract Operational scars, especially those located on the exposed parts of the body can be distressful. Despite high demand for an early intervention to minimize surgical scars, there is yet no universal consensus on optimal treatment. A split‐scar, double‐blind randomized controlled trial was held to assess the safety and efficacy of early postoperative botulinum toxin type A (BTA) injection in surgical scars. A single session of treatment was performed where BTA was allocated to one half of the scar, and 0.9% saline to the control half. Scars were assessed using the modified Stony Brook Scar Evaluation Scale (SBSES...
Source: Wound Repair and Regeneration - May 1, 2014 Category: Surgery Authors: Youn Sung Kim, Hyun Joo Lee, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim Tags: Original Research‐Clinical Science Source Type: research

Idiopathic Toe-Walking Have We Progressed in our Knowledge of the Causality and Treatment of this Gait Type?
Conclusions : This review updates the knowledge of podiatric physicians, enhances how children who present with this gait style can be managed, and highlights areas for future research. PMID: 24901584 [PubMed - in process] (Source: Journal of the American Podiatric Medical Association)
Source: Journal of the American Podiatric Medical Association - May 1, 2014 Category: Podiatry Authors: Williams CM, Tinley P, Rawicki B Tags: J Am Podiatr Med Assoc Source Type: research

Valeant launches hostile bid for Allergan
Botox maker swallows ‘poison pill’ in defence (Source: Chemistry World | Latest News)
Source: Chemistry World | Latest News - April 29, 2014 Category: Chemistry Authors: Phillip Broadwith Source Type: research

Botulinum Toxin Type A Injection Combined with Cast Immobilization for Treating Recurrent Peroneal Spastic Flatfoot without Bone Coalitions: A Case Report and Review of the Literature
We describe a 27-year-old female who experienced recurrent peroneal spastic flatfoot after an injury. She was treated successfully with a combination of botulinum toxin type A and immobilization of the foot in a neutral position with a cast. (Source: Journal of Foot and Ankle Surgery)
Source: Journal of Foot and Ankle Surgery - April 28, 2014 Category: Orthopaedics Authors: Jian Xu, Hassan Muhammad, Xu Wang, Xin Ma Tags: Case Reports and Series Source Type: research

Botulinum Toxin Type A Injection Combined with Cast Immobilization for Treating Recurrent Peroneal Spastic Flatfoot without Bone Coalitions: A Case Report and Review of the Literature
(Source: Journal of Foot and Ankle Surgery)
Source: Journal of Foot and Ankle Surgery - April 26, 2014 Category: Orthopaedics Authors: Jian Xu, Hassan Muhammad, Xu Wang, Xin Ma Source Type: research

Botulinum Toxin Type A Injection Combined with Cast Immobilization for Treating Recurrent Peroneal Spastic Flatfoot without Bone Coalitions: A Case Report and Review of the Literature
We describe a 27-year-old female who experienced recurrent peroneal spastic flatfoot after an injury. She was treated successfully with a combination of botulinum toxin type A and immobilization of the foot in a neutral position with a cast. (Source: Journal of Foot and Ankle Surgery)
Source: Journal of Foot and Ankle Surgery - April 26, 2014 Category: Orthopaedics Authors: Jian Xu, Hassan Muhammad, Xu Wang, Xin Ma Source Type: research

Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis
ConclusionsOur findings suggest that i.t. Onabot/A has a strong analgesic effect in a model of severe bladder pain. This route of administration can be further explored to treat intractable forms of pain. (Source: European Journal of Pain)
Source: European Journal of Pain - April 23, 2014 Category: Anesthesiology Authors: A. Coelho, R. Oliveira, O. Rossetto, C.D. Cruz, F. Cruz, A. Avelino Tags: Original Article Source Type: research

Efficacy of therapeutic ultrasound and transcutaneous electrical nerve stimulation compared with botulinum toxin type a in the treatment of spastic equinus in adults with chronic stroke: a pilot randomized controlled trial.
Conclusions: Our findings support the hypothesis that botulinum toxin type A is more effective than therapeutic ultrasound and TENS for treating focal spasticity in patients with chronic stroke. PMID: 24722047 [PubMed - in process] (Source: Topics in Stroke Rehabilitation)
Source: Topics in Stroke Rehabilitation - April 17, 2014 Category: Neurology Authors: Picelli A, Dambruoso F, Bronzato M, Barausse M, Gandolfi M, Smania N Tags: Top Stroke Rehabil Source Type: research

Treatment Adherence in Patients With Headache: A Systematic Review
ConclusionsAdherence research in adults with headache is growing, but studies demonstrate a number of methodological shortcomings. Adherence research in children with headache, and adherence intervention research in both adults and children, is scant. Future research should use objective measures of adherence, consider over‐the‐counter medications and medication overuse, examine demographic, psychological, and behavioral correlates of adherence, assess adherence to botulinum toxin type A, and examine the efficacy of adherence interventions in individuals with headache. (Source: Headache: The Journal of Head and Face Pain)
Source: Headache: The Journal of Head and Face Pain - April 17, 2014 Category: Neurology Authors: Rachelle R. Ramsey, Jamie L. Ryan, Andrew D. Hershey, Scott W. Powers, Brandon S. Aylward, Kevin A. Hommel Tags: Review Article Source Type: research

Treatment Adherence in Patients With Headache: A Systematic Review.
CONCLUSIONS: Adherence research in adults with headache is growing, but studies demonstrate a number of methodological shortcomings. Adherence research in children with headache, and adherence intervention research in both adults and children, is scant. Future research should use objective measures of adherence, consider over-the-counter medications and medication overuse, examine demographic, psychological, and behavioral correlates of adherence, assess adherence to botulinum toxin type A, and examine the efficacy of adherence interventions in individuals with headache. PMID: 24750017 [PubMed - as supplied by publish...
Source: Headache - April 17, 2014 Category: Neurology Authors: Ramsey RR, Ryan JL, Hershey AD, Powers SW, Aylward BS, Hommel KA Tags: Headache Source Type: research

Why Whitman-Walker is offering Botox to HIV patients
At first blush, adding cosmetic fillers like Botox and Juvederm to the lineup of offerings at Whitman-Walker Health — a federally qualified health center that specializes in HIV care — didn’t make a ton of sense. But Dr. Raymond Martins, chief medical officer at Whitman-Walker, was trying to hire a new nurse practitioner. The candidate sitting in front of him had a decade of experience in aesthetics. On further consideration, the mix made perfect sense. The injectable filler procedures… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 15, 2014 Category: Pharmaceuticals Authors: Tina Reed Source Type: research

Cortical Activity Modulation by Botulinum Toxin Type A in Patients with Post-Stroke Arm Spasticity: Real and Imagined Hand Movement (P1.142)
CONCLUSIONS:Study of 2 age-matched groups with mild and severe weakness demonstrated different effect of BoNT-lowered spasticity on motor system engagement. Group A during movement imagery at maximum BoNT effect manifested deactivation of visual and default mode system, perhaps a change from visual to kinesthetic imagery, with cerebellum participating. Group B during movement also manifested motor pattern normalization, especially reduced activation extent.Study Supported by: IGA MH CR grant NT13575.Disclosure: Dr. Hlustik has nothing to disclose. Dr. Veverka has nothing to disclose. Dr. Hok has nothing to disclose. Dr. Tu...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hlustik, P., Veverka, T., Hok, P., Tudos, Z., Otruba, P., Krobot, A., Kanovsky, P. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation and Recovery Source Type: research

A Randomized Controlled Trial Comparing Botulinum Toxin Type A Xeomin (R) and Dysport (R) for Treatment Of Primary Axillary Hyperhidrosis (P3.021)
CONCLUSIONSBoth AbobotulinumtoxinA and IncobotulinumtoxinA are safe and effective in the treatment of axillary hyperhidrosis. The different effectiveness of the two toxins documented by HDSS score may be related to underdosage or excessive dilution of Incobotulinum toxin: a new study in other 20 patients with axillary hyperhidrosis is ongoing, which compares IncobotulinumtoxinA, 100UI and AbobotulinumtoxinA, 250UI per axilla.Disclosure: Dr. Pastorelli has nothing to disclose. Dr. Michelucci has nothing to disclose. Dr. Plasmati has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Pastorelli, F., Michelucci, R., Plasmati, R. Tags: General Neurology II Source Type: research

A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A (P3.042)
CONCLUSIONS: OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/assessments and outcomes measures.Study Sponsored by: Allergan, Inc.Disclosure: Dr. Patel has received personal compensation for activities with Allergan Inc. Dr. Manack has received personal compensation for activities with Allergan Inc. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Patel, P., Manack, A. Tags: Neural Repair and Neuro-rehabilitation: Clinical Source Type: research

Response to IncobotulinumtoxinA After Resistance to OnabotulinumtoxinA and RimabotulinumtoxinB (P7.061)
CONCLUSIONS:Switching to incobotulinumtoxinA after secondary resistance to onabotulinumtoxinA and rimabotulinumtoxinB may be a viable treatment option in dystonia.Study Supported by:National Institutes of Health- National Institutes of Neurological Diseases and Stroke and the Dystonia Medical Research FoundationDisclosure: Dr. Ramos has received personal compensation for activities with the National Inistitutes of Health as an employee, and the Dystonia Medical Research Foundation. Dr. Karp has nothing to disclose. Dr. Lungu has nothing to disclose. Dr. Alter has nothing to disclose. Dr. Hallett has received personal compe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ramos, V., Karp, B., Lungu, C., Alter, K., Hallett, M. Tags: Movement Disorders: Dystonia Treatment Source Type: research

Clinical Audit of the Efficacy of Xeomin Against Dysport for the Treatment of Dystonia (P7.064)
CONCLUSION:The findings from this audit suggest that the conversion ratio to use to sustain optimal symptomatic relief when exchanging from Dysport to Xeomin is 3.64:1. We recommend that the protocol for the treatment of dystonia should be adjusted accordingly and that clinicians should consider titrating upwards to maintain optimal patient care.Disclosure: Dr. Meeks has nothing to disclose. Dr. Clough has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Meeks, D., Clough, C. Tags: Movement Disorders: Dystonia Treatment Source Type: research

Spinning Out of Control: The Black Box of Basilar and Hemiplegic Migraine (P7.176)
CONCLUSIONS:In this retrospective study, triptans were used effectively with no subsequent vascular events for the abortive treatment of migraines with basilar and hemiplegic features. This data also suggests that beta blockers, tricyclic anti-depressants, anti-convulsants, and Botox injections have some efficacy in the treatment of migraines with basilar type and hemiplegic features.Disclosure: Dr. Krel has nothing to disclose. Dr. Mathew has nothing to disclose. Dr. Spinner has received personal compensation for activities with Merz Pharma and Allergan Inc. as speaker bureau member. Dr. Joshi has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Krel, R., Mathew, P., Spinner, W., Joshi, S. Tags: Headache: Treatment Source Type: research

A Randomized, Open-Label, Parallel Two-Arm Study Evaluating the Efficacy of H.P. Acthar Injection Gel in the Treatment of Adults with Intractable Chronic Migraine (P7.182)
CONCLUSIONS:The hypothesis of this study is that Acthar will be effective in the treatment of intractable chronic migraine.This study is currently in the screening/enrollment phase.Study Supported by:Questcor PharmaceuticalsDisclosure: Dr. Mechtler has received personal compensation for activities with Zogenix Inc., Nautilus Neurosciences, Inc., and Allergan Inc. Dr. Mechtler's institute has received research support from GlaxoSmithKline, Inc., St. Jude Medical, Celldex Therapeutics, Inc., PharmaNet, and Spectrum Pharmaceuticals. Dr. Rothrock has received personal compensation for activities with Zogenix, MAP Pharmaceutica...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mechtler, L., Rothrock, J., Cady, R., McAllister, P. Tags: Headache: Treatment Source Type: research

Botulinum Toxin For Muscle Cramps Associated With Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study (S20.006)
CONCLUSIONS: BoNT/A can be a safe and promising treatment for painful cramps associated with diabetic neuropathy.Disclosure: Dr. Restivo has nothing to disclose. Dr. Gullo has nothing to disclose. Dr. Jann has received personal compensation for activities with Eli Lilly & Co., BioFutura Pharma, Abbott, and Kedrion. Dr. Vigneri has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Restivo, D., Pavone, A., Gullo, D., Jann, S., Vigneri, R. Tags: Pain and Palliative Care Source Type: research

New downtown Cincinnati dentist offers Botox, Netflix and fresh-baked cookies: EXCLUSIVE
A new dental office in downtown Cincinnati is aiming to offer the treatment and amenities commonly found in Hollywood or Manhattan dentists’ offices. Seven Star Dental, located at 7 W. Seventh St., next to Macy’s Inc.’s headquarters, is scheduled to open April 21. Dr. Shawna Battier, owner and principal dentist at Seven Star, said she saw an opportunity with more people living and working downtown, and she wants Cincinnatians to be pampered while they have their teeth worked on. “I want… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 7, 2014 Category: Pharmaceuticals Authors: Tom Demeropolis Source Type: research

34. Modulation of cortical activity by botulinum toxin type a in patients with post-stroke arm spasticity
Conclusion: Study of 2 age-matched groups with mild and severe weakness demonstrated different effect of BoNT-lowered spasticity on motor system engagement. Group A during movement imagery at maximum BoNT effect manifested deactivation of visual and default mode system, perhaps a change from visual to kinesthetic imagery, with cerebellum participating. Group B during movement also manifested motor pattern normalization, especially reduced activation extent.Supported by IGA MZ CR NT13575. (Source: Clinical Neurophysiology)
Source: Clinical Neurophysiology - April 7, 2014 Category: Neuroscience Authors: P. Hluštík, T. Veverka, P. Hok, Z. Tüdös, P. Otruba, A. Krobot, P. Kaňovský Tags: Society Proceedings Source Type: research

28. Modulation of cerebral sensorimotor circuits during botulinum toxin treatment of cervical dystonia
Discussions: Within the context of previously described sensorimotor network hypoactivation during motor task performance in CD, our observed effect of no significant change in sensorimotor cortex activation would suggest the hypothesis that robust central changes develop after long-term regular BoNT-A treatment, although even the first BoNT-A application is clinically effective.Acknowledgment: Research supported by Grant IGA MH CR NT13575. (Source: Clinical Neurophysiology)
Source: Clinical Neurophysiology - April 7, 2014 Category: Neuroscience Authors: M. Nevrly, P. Hlustik, P. Otruba, R. Opavsky, P. Hok, P. Kanovsky Tags: Society Proceedings Source Type: research

Onabotulinum A (Botox)
(Source: Headache: The Journal of Head and Face Pain)
Source: Headache: The Journal of Head and Face Pain - April 2, 2014 Category: Neurology Authors: Deborah Tepper Tags: Headache Toolbox Source Type: research

La toxina botulínica tipo A (Botox)
(Source: Headache: The Journal of Head and Face Pain)
Source: Headache: The Journal of Head and Face Pain - April 2, 2014 Category: Neurology Authors: Deborah Tepper, Traducido por Cristina M. Cabret‐Aymat Tags: Headache Toolbox Source Type: research

La toxina botulínica tipo A (Botox).
La toxina botulínica tipo A (Botox). Headache. 2014 Apr;54(4):789-90 Authors: Tepper D, Cabret-Aymat TP PMID: 24697236 [PubMed - in process] (Source: Headache)
Source: Headache - April 1, 2014 Category: Neurology Authors: Tepper D, Cabret-Aymat TP Tags: Headache Source Type: research

Onabotulinum a (botox).
PMID: 24697235 [PubMed - in process] (Source: Headache)
Source: Headache - April 1, 2014 Category: Neurology Authors: Tepper D Tags: Headache Source Type: research

Restorative proctocolectomy with J-pouch ileoanal anastomosis for total colonic aganglionosis among neonates and infants
Conclusions: The rate of postoperative enterocolitis was similar to other procedures, but a better functional outcome was achieved. Botox injections were effective for postoperative functional outlet obstruction. Short-term results following RPC among neonates and infants are promising. (Source: Journal of Pediatric Surgery)
Source: Journal of Pediatric Surgery - April 1, 2014 Category: Surgery Authors: Maria Hukkinen, Antti Koivusalo, Risto J. Rintala, Mikko P. Pakarinen Tags: Original Articles Source Type: research

The study of cellular cytotoxicity of argireline® - an anti-aging peptide.
In conclusion, the considered method resulted in dose-dependent argireline® anti-proliferation effects. However, the significant cytotoxicity of argireline® solution was observed under 18 to 10 000 fold higher concentrations (depending on cells that were examined) in comparison to doxorubicin. PMID: 24644551 [PubMed - as supplied by publisher] (Source: Acta Biochim Pol)
Source: Acta Biochim Pol - March 17, 2014 Category: Biochemistry Authors: Grosicki M, Latacz G, Szopa A, Cukier A, Kieć-Kononowicz K Tags: Acta Biochim Pol Source Type: research

Effects of Botulinum Toxin on Jaw Motor Events during Sleep in Sleep Bruxism Patients: A Polysomnographic Evaluation
Study Objectives:To investigate the effects of botulinum toxin type A (BoNT-A) injection on jaw motor episodes during sleep in patients with or without orofacial pain who did not respond to oral splint treatment.Methods:Twenty subjects with a clinical diagnosis of SB completed this study. Ten subjects received bilateral BoNT-A injections (25 U per muscle) into the masseter muscles only (group A), and the other 10 received the injections into both the masseter and temporalis muscles (group B). Video-polysomnographic (vPSG) recordings were made before and at 4 weeks after injection. Rhythmic masticatory muscle activity (RMMA...
Source: Journal of Clinical Sleep Medicine : JCSM - March 15, 2014 Category: Sleep Medicine Source Type: research

Question 2: Is there any long-term benefit from injecting botulinum toxin-A into children with cerebral palsy?
Clinical scenario A 5-year-old girl with diplegic cerebral palsy has been seen regularly since the age of 3 years. As part of the management for lower limb spasticity, she has undergone three previous intramuscular botulinum toxin A injections (BoTN-A) to her gastrocnemii. During the consent process for a further injection, the mother asks if this treatment will be of benefit to her daughter in the future. Clinical question In children with cerebral palsy receiving intramuscular injection of BoTN-A is there any clinically relevant long-term (greater than 1 year) effect? Search A literature search was performed in...
Source: Archives of Disease in Childhood - March 13, 2014 Category: Pediatrics Authors: Bradley, L. J., Huntley, J. S. Tags: ADC Archimedes, Clinical trials (epidemiology), Cerebral palsy, Foodborne infections, Drugs: CNS (not psychiatric), Neuromuscular disease, Child health, Rheumatology, Dentistry and oral medicine, Poisoning, Occupational and environmental medicine, Guideli Source Type: research